Press Release – New York, NY – July 13, 2017 – Securities and corporate law firm Carmel, Milazzo & Feil LLP announced today that it has represented Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests, in a $7 Million Initial Public Offering on the NASDAQ.
Co-Diagnostics, Inc. sold 1,178,532 shares of common stock at a price of $6.00 per share in the offering for aggregate gross proceeds of $7,071,192.
WallachBeth Capital, LLC and Network 1 Financial Securities, Inc. acted as co-book running managers for the offering and ViewTrade Securities, Inc. acted as co-manager.
Co-Diagnostics’ registration statement relating to these securities was declared effective as of July 11, 2017 by the U.S. Securities and Exchange Commission. Copies of the final prospectus may be obtained on the SEC’s website, http://www.sec.gov, and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 100 Wall Street, Suite 6600, New York, NY 10005, by telephone at 646-998-7605, or by email at cap-mkts@wallachbeth.com or Network 1 Financial Securities, Inc. by telephone at 800-886-7007 or by mail at 2 Bridge Avenue, Suite 241, Redbank, NJ 07701.
